<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726009</url>
  </required_header>
  <id_info>
    <org_study_id>000201</org_study_id>
    <nct_id>NCT02726009</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer</brief_title>
  <official_title>An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate
      long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced
      hormone-dependent prostate cancer requiring androgen deprivation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Up to Day 364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Up to Day 364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in laboratory values (hematology and clinical biochemistry)</measure>
    <time_frame>From baseline to Day 364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>From baseline to Day 364</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of no Prostate Specific Antigen (PSA) failure</measure>
    <time_frame>Up to Day 364</time_frame>
    <description>PSA failure defined as an increase in serum PSA of 50%, and at least 5 ng/mL, compared to nadir, measured on two consecutive occasions at least 2 weeks apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of Progression Free Survival (PFS)</measure>
    <time_frame>Up to Day 364</time_frame>
    <description>PFS defined as PSA failure, death from any cause, or introduction of additional therapy related to prostate cancer, whichever is first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>From baseline to Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician's satisfaction score</measure>
    <time_frame>From baseline to Day 364</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <arm_group_label>Degarelix</arm_group_label>
    <other_name>Firmagon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has given written informed consent before any study-related activity is performed

          -  Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is
             indicated, and independently from this trial, Firmagon® is intended to be used for
             treatment

          -  Age greater than or equal to 18 years and less than 80 years

          -  Advanced hormone-dependent prostate cancer without any other clinically significant
             disorder

          -  Easten Cooperative Oncology Group score ≤ 2

          -  PSA ≥ 2 ng/mL at screening

          -  Life expectancy of at least 12 months as per the investigator's judgement

        Exclusion Criteria:

          -  Previous or concurrent hormonal management of prostate cancer

          -  Contraindication for prescription of Firmagon®

          -  Concurrent treatment with a 5-α-reductase inhibitor

          -  Considered as a candidate for curative therapy

          -  History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or
             angioedema

          -  QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and
             Class III anti arrhythmic medications

          -  Cancer within the last 5 years except prostate cancer and surgically removed basal or
             squamous cell carcinoma of the skin

          -  Known or suspected hepatic, symptomatic biliary disease (this includes moderate to
             severe chronic hepatic impairment)

          -  Patients with clinically significant laboratory abnormalities / disorders other than
             prostate cancer

          -  Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human
             Immunodeficiency Virus (HIV) infections
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S. P Medical College and AG of Hospitals</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Secunderabad</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodyline Hospitals</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG Multi Specialty Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalby Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthCare Global Enterprises Limited</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLE's Dr. Prabhakar Kore Hospital &amp; MRC</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute and Research Centre</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muljibhai Patel Urological Hospital</name>
      <address>
        <city>Gujrat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHL Hospital</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Medical College &amp; Attached Hospital's</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Medical Center</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's George Medical University</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College and Super Specialty Hospital</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rml &amp; Pgimer</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aman Hospital and Research Center</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

